FDA approval: Idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma

Clinical Cancer Research

Volumn 21, Issue 7, 2015, Pages 1525-1529

  Miller, Barry W ^a   Przepiorka, Donna ^a   De Claro, R Angelo ^a   Lee, Kyung ^a   Nie, Lei ^a   Simpson, Natalie ^a   Gudi, Ramadevi ^a   Saber, Haleh ^a   Shord, Stacy ^a   Bullock, Julie ^a   Marathe, Dhananjay ^a   Mehrotra, Nitin ^a   Hsieh, Li Shan ^a   Ghosh, Debasis ^a   Brown, Janice ^a   Kane, Robert C ^a   Justice, Robert ^a   Kaminskas, Edvardas ^a   Farrell, Ann T ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN; IDELALISIB; MIDAZOLAM; ROSUVASTATIN; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ARTICLE; ASTHENIA; CANCER RECURRENCE; CLINICAL PHARMACOLOGY; COLITIS; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INSOMNIA; INTESTINE PERFORATION; LIVER TOXICITY; LYMPHOCYTOMA; MONOTHERAPY; NAUSEA; NEUTROPENIA; NIGHT SWEAT; NONHUMAN; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; RASH; RESPIRATORY FAILURE; RISK BENEFIT ANALYSIS; THROMBOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANTAGONISTS AND INHIBITORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR;

ANTINEOPLASTIC AGENTS; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; PURINES; QUINAZOLINONES;

EID: 84927673054     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2522     Document Type: Article

References (17)

1. Freedman A. Follicular lymphoma: 2014 update on diagnosis and management. Am J Hematol 2014;89:430-6.
2. Lunning MA, Vose JM. Management of indolent lymphoma: where are we now and where are we going. Blood Rev 2012;26:279-88.
3. PDQ®-NCI's Comprehensive Database [database on the Internet]. Bethesda (MD): National Cancer Institute [updated 2014 Aug 22; cited 2014 Sep 26]. Adult non-Hodgkin lymphoma treatment PDQ®; [about 3 screens]. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins/HealthProfessional. Files updated several times a year.
4. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al., editors. SEER cancer statistics review(CSR), 1975-2011 [monograph on the Internet]. Bethesda (MD): National Cancer Institute; 2014 [cited 2014 Sep 26]. Available from: http://seer.cancer.gov/csr/1975-2011/.
5. Drugs@FDA [database on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; c1997 [cited 2014 Sep 26]. Rituxan prescribing information (2 p.). Available from: http://www.accessdata.fda.gov/drug-satfda-docs/label/1997/ritugen112697-lab.pdf. Files updated daily.
6. Drugs@FDA [database on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; c2002 [cited 2014 Sep 26]. Zevalin prescribing information (38 p.). Available from: http://www.accessdata.fda.gov/drug-satfda-docs/label/2002/ibriide021902LB.pdf. Files updated daily.
7. Drugs@FDA [database on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; c2008 [cited 2014 Sep 26]. Treanda prescribing information (6 p.). Available from: http://www.accessdata.fda.gov/drug-satfda-docs/label/2008/022249lbl.pdf. Files updated daily.
8. Puri KD, Gold MR. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol 2012;3:256.
9. Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013;12:229-43.
10. Schrottner P, Leick M, Burger M. The role of chemokines in B cell chronic lymphocytic leukaemia: pathophysiological aspects and clinical impact. Ann Hematol 2010;89:437-46.
11. Drugs@FDA [database on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; cJuly 2014 [cited 2014 Sep 26]. Zydelig for relapsed chronic lymphocytic leukemia medical review; [77 p.]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/206545Orig1s000MedR.pdf. Files updated daily.
12. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008-18.
13. Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014;123:3406-13.
14. Cheson BD, P fistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
15. Guidance for industry: expedited programs for serious conditions - drugs and biologics [PDF on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; c2014 [cited 2014 Sep 25]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm358301.pdf
16. Jones JA, Byrd JC. How will B-cell-receptor -targeted therapies change future CLL therapy? Blood 2014;123:1455-60.
17. Drugs@FDA [database on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; c2014 [cited 2014 Aug 22]. Zydelig approval letter (11 p.). Available from: http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2014/205858Orig1s000ltr.pdf